A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003)
NCT ID: NCT06619665
Last Updated: 2024-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
18 participants
INTERVENTIONAL
2024-03-19
2024-07-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)
NCT06179407
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults
NCT03522506
Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia
NCT03772314
Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy
NCT00066170
Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy
NCT00107796
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MK-6552-Placebo-Modafinil
Participants were treated in period 1 with MK-6552; in period 2 with placebos to Modafinil and MK-6552; and in period 3 with Modafinil; with a 7-day washout between each period.
MK-6552
MK-6552 gelatin coated capsules taken orally two times 8 hours apart
MK-6552 placebo
MK-6552 placebo gelatin coated capsules taken orally two times 8 hours apart
Modafinil
Modafinil tablet taken once orally
Modafinil placebo
Modafinil placebo tablet taken once orally
MK-6552-Modafinil-Placebo
Participants were treated in period 1 with MK-6552; in period 2 with Modafinil; and in period 3 with placebos to Modafinil and MK-6552; with a 7-day washout between each period.
MK-6552
MK-6552 gelatin coated capsules taken orally two times 8 hours apart
MK-6552 placebo
MK-6552 placebo gelatin coated capsules taken orally two times 8 hours apart
Modafinil
Modafinil tablet taken once orally
Modafinil placebo
Modafinil placebo tablet taken once orally
Placebo-Modafinil-MK-6552
Participants were treated in period 1 with placebos to Modafinil and MK-6552; in period 2 with Modafinil; and in period 3 with MK-6552; with a 7-day washout between each period.
MK-6552
MK-6552 gelatin coated capsules taken orally two times 8 hours apart
MK-6552 placebo
MK-6552 placebo gelatin coated capsules taken orally two times 8 hours apart
Modafinil
Modafinil tablet taken once orally
Modafinil placebo
Modafinil placebo tablet taken once orally
Placebo-MK-6552-Modafinil
Participants were treated in period 1 with placebos to Modafinil and MK-6552; in period 2 with MK-6552; and in period 3 with Modafinil; with a 7-day washout between each period.
MK-6552
MK-6552 gelatin coated capsules taken orally two times 8 hours apart
MK-6552 placebo
MK-6552 placebo gelatin coated capsules taken orally two times 8 hours apart
Modafinil
Modafinil tablet taken once orally
Modafinil placebo
Modafinil placebo tablet taken once orally
Modafinil-MK-6552-Plaebo
Participants were treated in period 1 with Modafinil; in period 2 withMK-6552; and in period 3 with placebos to Modafinil and MK-6552; with a 7-day washout between each period.
MK-6552
MK-6552 gelatin coated capsules taken orally two times 8 hours apart
MK-6552 placebo
MK-6552 placebo gelatin coated capsules taken orally two times 8 hours apart
Modafinil
Modafinil tablet taken once orally
Modafinil placebo
Modafinil placebo tablet taken once orally
Modafinil-Plaebo-MK-6552
Participants were treated in period 1 with Modafinil; in period 2 with placebos to Modafinil and MK-6552; and in period 3 with MK-6552; with a 7-day washout between each period.
MK-6552
MK-6552 gelatin coated capsules taken orally two times 8 hours apart
MK-6552 placebo
MK-6552 placebo gelatin coated capsules taken orally two times 8 hours apart
Modafinil
Modafinil tablet taken once orally
Modafinil placebo
Modafinil placebo tablet taken once orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MK-6552
MK-6552 gelatin coated capsules taken orally two times 8 hours apart
MK-6552 placebo
MK-6552 placebo gelatin coated capsules taken orally two times 8 hours apart
Modafinil
Modafinil tablet taken once orally
Modafinil placebo
Modafinil placebo tablet taken once orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Is in good health
* Body Mass Index (BMI) between 18 and 32 kg/m\^2, inclusive.
Exclusion Criteria
* History of or current hypertension,
* Has a history of sleep disorders:
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NeuroTrials Research Inc (Site 0001)
Atlanta, Georgia, United States
Clinilabs (Site 0003)
Eatontown, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-6552-003
Identifier Type: OTHER
Identifier Source: secondary_id
6552-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.